Abstract 2752
Background
Recent targeted therapies such as poly-ADP ribose polymerase inhibitors (PARPi) and angiogenesis inhibitors (AI) are known to ease burden and recurrence of ovarian cancer. This network meta-analysis conducted an indirect treatment comparison between PARPi, AI and chemotherapeutic agents (CTA) in terms of clinical efficacy and safety as maintenance therapy in ovarian cancer patients irrespective of BRCA status.
Methods
We searched relevant sources (PubMed, EMBASE) to identify randomized controlled trials in ovarian cancer patients undergoing maintenance therapy. Studies assessing efficacy and safety of PARPi (n = 4), AIs (n = 12), CTA (n = 8) with placebo were analyzed. Primary outcome included progression free survival (PFS), safety and tolerability were secondary outcomes. A network meta-analysis to compare 3 drug classes was performed using statistical software R.
Results
PARPi [Hazard Ratio (HR) =0.64; 95% Credible Intervals (CrI) =0.55-0.73] and AI (HR = 0.87; 95% CrI=0.81-0.93) showed significant improvement in PFS compared to placebo but not CTA (HR = 1.00; 95% CrI=0.86-1.15, Table). PARPi showed significant improvement in PFS compared to AI (HR = 0.73; 95% CrI=0.63-0.86) and CTA (HR = 0.64; 95% CrI=0.52-0.78). Adverse events (AEs) leading to treatment discontinuation and dose reduction were lower in PARPi [Incidence Rate Ratio (IRR) =1.64; CrI=0.84-3.19, IRR=0.73, 95% CrI=0.50-1.06 respectively] compared to AI, but not significant.Table: 976P
Comparison of PFS data across different therapies
| Treatment | AI | CTA | PARPi | Placebo |
|---|---|---|---|---|
| AI | - | 1.14 (0.98, 1.35) | 0.73 (0.63, 0.86) | 1.15 (1.07, 1.24) |
| CTA | 0.87 (0.74, 1.02) | - | 0.64 (0.52, 0.78) | 1.00 (0.87, 1.16) |
| PARPi | 1.37 (1.16, 1.6) | 1.57 (1.28, 1.92) | - | 1.57 (1.36, 1.81) |
| Placebo | 0.87 (0.81, 0.93) | 1.00 (0.86, 1.15) | 0.64 (0.55, 0.73) | - |
AI angiogenesis inhibitors; CTA chemotherapeutic agents; PARPi poly ADP ribose polymerase inhibitors.
Conclusions
PARPi as maintenance treatment improved PFS in ovarian cancer and was relatively safer in terms of AEs caused implications when compared to other therapies. This network meta-analysis provides valuable evidence and significant insights in treatment of ovarian cancer.
Clinical trial identification
Legal entity responsible for the study
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou.
Funding
AstraZeneca.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract